BACKGROUND: Smokers are exposed to significant doses of carcinogens, including tobacco-specific nitrosamines (TSNA). Previous studies have shown significant global differences in the levels of TSNAs in cigarette smoke because of the variation in tobacco blending and curing practices around the world. METHODS: Mouth-level exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) measured in cigarette butts and urinary concentrations of its major metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) were examined among 126 daily smokers in four countries over a 24-hour study period. RESULTS: As mouth-level exposure of NNK increased, the urinary NNAL increased even after adjustment for other covariates (beta = 0.46, P = 0.004). The relationship between mouth-level exposure to nicotine and its salivary metabolite, cotinine, was not statistically significant (beta = 0.29, P = 0.057), likely because of the very limited range of differences in mouth-level nicotine exposure in this population. CONCLUSIONS: We have shown a direct association between the 24-hour mouth-level exposure of NNK resulting from cigarette smoking and the concentration of its primary metabolite, NNAL, in the urine of smokers. Internal dose concentrations of urinary NNAL are significantly lower in smokers in countries that have lower TSNA levels in cigarettes such as Canada and Australia in contrast to countries that have high levels of these carcinogens in cigarettes, such as the United States. IMPACT: Lowering the levels of NNK in the mainstream smoke of cigarettes through the use of specific tobacco types and known curing practices can significantly affect the exposure of smokers to this known carcinogen. Copyright 2010 AACR.
BACKGROUND: Smokers are exposed to significant doses of carcinogens, including tobacco-specific nitrosamines (TSNA). Previous studies have shown significant global differences in the levels of TSNAs in cigarette smoke because of the variation in tobacco blending and curing practices around the world. METHODS: Mouth-level exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) measured in cigarette butts and urinary concentrations of its major metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) were examined among 126 daily smokers in four countries over a 24-hour study period. RESULTS: As mouth-level exposure of NNK increased, the urinary NNAL increased even after adjustment for other covariates (beta = 0.46, P = 0.004). The relationship between mouth-level exposure to nicotine and its salivary metabolite, cotinine, was not statistically significant (beta = 0.29, P = 0.057), likely because of the very limited range of differences in mouth-level nicotine exposure in this population. CONCLUSIONS: We have shown a direct association between the 24-hour mouth-level exposure of NNK resulting from cigarette smoking and the concentration of its primary metabolite, NNAL, in the urine of smokers. Internal dose concentrations of urinary NNAL are significantly lower in smokers in countries that have lower TSNA levels in cigarettes such as Canada and Australia in contrast to countries that have high levels of these carcinogens in cigarettes, such as the United States. IMPACT: Lowering the levels of NNK in the mainstream smoke of cigarettes through the use of specific tobacco types and known curing practices can significantly affect the exposure of smokers to this known carcinogen. Copyright 2010 AACR.
Authors: Lion Shahab; David Hammond; Richard J O'Connor; K Michael Cummings; Ron Borland; Bill King; Ann McNeill Journal: Nicotine Tob Res Date: 2008-05 Impact factor: 4.244
Authors: S S Hecht; S G Carmella; M Chen; J F Dor Koch; A T Miller; S E Murphy; J A Jensen; C L Zimmerman; D K Hatsukami Journal: Cancer Res Date: 1999-02-01 Impact factor: 12.701
Authors: Yang Xia; James E McGuffey; Sumita Bhattacharyya; Börje Sellergren; Ecevit Yilmaz; Lanqing Wang; John T Bernert Journal: Anal Chem Date: 2005-12-01 Impact factor: 6.986
Authors: Dorothy K Hatsukami; Charlotte Lemmonds; Yan Zhang; Sharon E Murphy; Chap Le; Steven G Carmella; Stephen S Hecht Journal: J Natl Cancer Inst Date: 2004-06-02 Impact factor: 13.506
Authors: David L Ashley; Michelle D Beeson; Diana R Johnson; Joan M McCraw; Patricia Richter; James L Pirkle; Terry F Pechacek; Siqing Song; Clifford H Watson Journal: Nicotine Tob Res Date: 2003-06 Impact factor: 4.244
Authors: Nada O F Kassem; Noura O Kassem; Sandy Liles; Sheila R Jackson; Dale A Chatfield; Peyton Jacob; Neal L Benowitz; Melbourne F Hovell Journal: Regul Toxicol Pharmacol Date: 2017-07-14 Impact factor: 3.271
Authors: Irina Stepanov; Aleksandar Knezevich; Liqin Zhang; Clifford H Watson; Dorothy K Hatsukami; Stephen S Hecht Journal: Tob Control Date: 2011-05-20 Impact factor: 7.552
Authors: Tracy T Smith; Joseph S Koopmeiners; Dorothy K Hatsukami; Katelyn M Tessier; Neal L Benowitz; Sharon E Murphy; Andrew A Strasser; Jennifer W Tidey; Benjamin C Blount; Liza Valentin; Roberto Bravo Cardenas; Clifford Watson; James L Pirkle; Eric C Donny Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-02-26 Impact factor: 4.254
Authors: Gary A Giovino; Gary E Swan; Ben Blount; Stephanie O'Malley; Darigg C Brown; Tabitha P Hendershot Journal: Tob Control Date: 2020-01 Impact factor: 7.552
Authors: M Alexandre; A K Uduman; S Minervini; A Raoof; C A Shugrue; E O Akinbiyi; V Patel; M Shitia; T R Kolodecik; R Patton; F S Gorelick; E C Thrower Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-07-26 Impact factor: 4.052
Authors: Ban Majeed; Daniel Linder; Thomas Eissenberg; Yelena Tarasenko; Danielle Smith; David Ashley Journal: Prev Med Date: 2020-07-18 Impact factor: 4.018